Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative (HR+/HER2-) breast cancer treatment has made a breakthrough due to the introduction of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors. This evidence concerns the gene NR4A1 and breast carcinoma.